Viridian (VRDN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$71.1M

Revenue (quarter)

$284,000.00

Revenue growth (year over year)

+278.67%

Gross profit (trailing twelve months)

$71.1M

Gross margin

100.00%

Net income (trailing twelve months)

−$387.0M

Net income (quarter)

−$127.1M

Net income growth (year over year)

−26.19%

Net margin

−544.06%

Return on equity

−65.74%

EPS (trailing twelve months)

−$3.40

Book value per share

$4.98

P/E (trailing twelve months)

—

Price to book

3.24

Debt to assets

39.66%

Payout ratio

—

Dividend yield

—

Company profile

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

• Is Viridian (VRDN) profitable?

  No. Viridian reported a net loss of $387.0M over the trailing twelve months.

• How much revenue does Viridian (VRDN) make?

  Viridian generated $71.1M in revenue over the trailing twelve months, up 278.67% year over year.

• How do I buy stock in Viridian (VRDN)?

  VRDN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.